This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Smallpox vaccine
Description: ACAM2000 is derived from Dryvax, the original smallpox vaccine. Unlike Dryvax, which contained a mixture of vaccinia clones, ACAM2000 contains a single clone. The vaccinia clone in ACAM2000 is stable and less virulent than some clones found in Dryvax.
ACAM2000 is given by scarification (a droplet is placed on the skin, and then the skin is jabbed with a needle). ACAM2000 should not be injected by the intradermal, subcutaneous, intramuscular, or intravenous route. BMT classifies scarification as a topical application.
Deal Structure: In July 2008, Sanofi-aventis announced it reached an agreement with Acambis on the terms of a unanimously recommended cash offer for the entire issued and to be issued share capital of Acambis. The acquisition was closed in September 2008.
Pink Sheet Weekly Trademark Review Aug. 23, 2016
Additional information available to subscribers only: